Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.

[1]  Michaela A. E. Arndt,et al.  High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Michaela A. E. Arndt,et al.  A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells , 2015, Journal of immunology research.

[3]  R. Schibli,et al.  Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy. , 2015, Nuclear medicine and biology.

[4]  F. Szoka,et al.  The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. , 2015, Advanced drug delivery reviews.

[5]  T. Witzig,et al.  Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma , 2014, Haematologica.

[6]  F. Kampmeier,et al.  Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA) , 2014, EJNMMI Research.

[7]  R. Herrmann,et al.  Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas , 2013, The Journal of Nuclear Medicine.

[8]  R. O’Donnell,et al.  Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook , 2013, BioDrugs.

[9]  Yanli Wang,et al.  Expression Systems and Species Used for Transgenic Animal Bioreactors , 2013, BioMed research international.

[10]  J. Tomlinson,et al.  An Engineered Cysteine-Modified Diabody for Imaging Activated Leukocyte Cell Adhesion Molecule (ALCAM)-Positive Tumors , 2012, Molecular Imaging and Biology.

[11]  J. Tomlinson,et al.  Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. , 2011, The Journal of surgical research.

[12]  J. Bading,et al.  Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging. , 2011, Bioconjugate chemistry.

[13]  D. Huglo,et al.  High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Wu,et al.  ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). , 2010, Protein engineering, design & selection : PEDS.

[15]  F. Forrer,et al.  In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  W. Mcbride,et al.  Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma , 2009, Journal of Nuclear Medicine.

[17]  A. Kribben,et al.  Serum cystatin C in mouse models: a reliable and precise marker for renal function and superior to serum creatinine. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  D. Greiner,et al.  Non‐obese diabetic–recombination activating gene‐1 (NOD–Rag 1 null) interleukin (IL)‐2 receptor common gamma chain (IL 2 rγnull) null mice: a radioresistant model for human lymphohaematopoietic engraftment , 2008, Clinical and experimental immunology.

[19]  D. Maloney,et al.  Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. , 2007, Blood.

[20]  M. Brechbiel,et al.  Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. , 2007, Nuclear medicine and biology.

[21]  Paul J Yazaki,et al.  Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. , 2006, Bioconjugate chemistry.

[22]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.

[23]  Michaela A. E. Arndt,et al.  Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein. , 2005, Biochemical and biophysical research communications.

[24]  D. Goldenberg,et al.  177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. , 2005, Nuclear medicine and biology.

[25]  M. Brechbiel,et al.  A Single Treatment of Yttrium-90-labeled CHX-A″–C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice , 2004, Cancer Research.

[26]  M. Brechbiel,et al.  Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.

[27]  E. Wolf,et al.  Stable Production of Human Insulin-like Growth Factor 1 (IGF-1) in the Milk of Hemi- and Homozygous Transgenic Rabbits Over Several Generations , 1998, Transgenic Research.

[28]  Sanjiv S Gambhir,et al.  124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  Andrew C. R. Martin,et al.  Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment. , 2003, Protein engineering.

[30]  Jianglin Fan,et al.  Transgenic rabbits as therapeutic protein bioreactors and human disease models. , 2003, Pharmacology & therapeutics.

[31]  L. Gordon,et al.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  G. Griffiths,et al.  Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  L. Chappell,et al.  Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. , 2000, Nuclear medicine and biology.

[35]  G. Brem,et al.  Human nerve growth factor beta (hNGF‐β): mammary gland specific expression and production in transgenic rabbits , 1999, FEBS letters.

[36]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[38]  A. Giaccia,et al.  scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R K Jain,et al.  Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.